LncRNA prostate androgen-regulated transcript 1 (PART1) has been found to confer the resistance to gefitinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), through regulating miR-129/Bcl-2 pathway in ESCC cells. Here, BCL2 is linked to esophageal squamous cell carcinoma.